Antiretroviral Activity of Emtricitabine,a Potent Nucleoside Reverse Transcriptase Inhibitor

Hammer S.M. , Squires K.E. , Hughes M.D. , Grimes J.M. , Demeter L.M. , Currier J.S. , Eron J.J. Jr. , Feinberg J.E. , Balfour H.H. Jr. , Deyton L.R. , Chodakewitz J.A. , & Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337: 725–733.

Palella F.J. Jr. , Delaney K.N. , Moorman A.C. , Loveless M.O. , Fuhrer J. , Satten G.A. , Aschman D.J. , & Holmberg SD for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338: 853–860.

Carpenter C.C.J. , Cooper D.A. , Fischl M.A. , Gatell J.M. , Gazzard B.G. , Hammer S.M. , Hirsch M.S. , Jacobsen D.M. , Katzenstein D.A. , Montaner J.S.G. , Richman D.D. , Saag M.S. , Schechter M. , Schooler R.T. , Vella S. , Yeni P.G. , & Volberding P.A. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society–USA panel. Journal of the American Medical Association 2000; 283: 381–390.

Schinazi R.F. , McMillan A. , Cannon D. , Mathis R. , Lloyd R.M. , Peck A. , Sommadossi J-P , St Clair M. , Wilson J. , Furman P.A. , Painter G. , Choi W-B , & Liotta C. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxy-methyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrobial Agents & Chemotherapy 1992; 36: 2423–2431.

Furman P.A. , Wilson J.E. , Reardon J.E. , & Painter G.R. The effect of absolute configuration on the anti-HIV and anti-HBV activity of nucleoside analogues. Antiviral Chemistry & Chemotherapy 1995; 6: 345–355.

Painter G.R. , St Clair M. , Ching S. , Noblin J. , Wang L.H. , & Furman P.A. 524W91: anti-HIV, anti-hepatitis B virus. Drugs of the Future 1995; 20: 761–765.

Cui L. , Schinazi R.F. , Gosselin G. , Imbach J-L , Chu C.K. , Rando R.F. , Revankan G.R. , & Sommadossi J-P Effect of β-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells: implications for predicting drug hepatotoxicity. Biochemical Pharmacology 1996; 52: 1577–1584.

Feng J.Y. , Shi J. , Schinazi R.F. , & Anderson K.S. Mechanistic studies show that (–)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. The FASEB Journal 1999; 13: 1511–1517.

Schinazi R.F. , Chu C.K. , Peck A. , McMillan A. , Mathis R. , Cannon D. , Jeong L-S , Beach J.W. , Choi W-B , Yeola S. , & Liotta D.C. Activities of the four optical isomers of 2’,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrobial Agents & Chemotherapy 1992; 36: 672–676.

Mathez D. , Schinazi D.F. , Liotta D.C. , & Leibowitch J. Infectious amplification of wild-type human immunodeficiency virus from patients’ lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrobial Agents & Chemotherapy 1993; 37: 2206–2211.

Schinazi R.F. , Lloyd R.M. Jr. , Nguyen M. , Cannon D.L. , McMillan A. , Ilksoy N. , Chu C.K. , Liotta D.C. , Bazmi H.Z. , & Mellors J.W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents & Chemotherapy 1993; 37: 875–881.

Tisdale M. , Kemp S.D. , Parry N.R. , & Larder B.A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences (USA) 1993; 90: 5653–5656.

Boucher C.A.B. , Cammack N. , Schipper P. , Schuurman R. , Rouse P. , Wainberg M.A. , & Cameron J.M. High-level resistance to (–) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy 1993; 37: 2231–2234.

Bridges E.G. , Dutschman G.E. , Gullen E.A. , & Cheng Y. Favorable interaction of β-l(–) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochemical Pharmacology 1996; 51: 731–736.

Grizzle T.B. , Delehanty J. , Wang L.H. , Rousseau F.S. , & Szczech G.M. Preclinical safety evaluation of emtricitabine (Coviracil). 13th World AIDS Conference, Durban, South Africa, July 2000; Abstract WePeA4058.

Grizzle T. , Rousseau F. , Delehanty J. , Hart R. , Walsh J. , Wang L. , Schardein J. , Stump D. , Tyl R. , & Szczech G. Preclinical reproductive and developmental safety profile of Coviracil (emtricitabine, FTC), an oxathiolane nucleoside analog for the treatment of HIV and HBV infection. Infectious Diseases Society of America Annual Meeting, Philadelphia, Pa., November 1999; Abstract 100211.

Feng J.Y. , Johnson A.A. , Johnson K.A. , Schinazi R.F. , Anderson K.S. , & Furman P.A. Insights into the molecular mechanism of mitochondrial toxicity of antiviral drugs. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, September 2000; Abstract. P17.

Kahn J.O. , Rousseau F. , Thompson M. , Mildvan D. , Shepp D. , Sommadossi J-P , McCreedy B. , Delehanty J. , Wang L.H. , Blum M.R. , Quinn J. , Wakeford C. , Barry D.W. , & van der Horst C. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil), In Press.

Kahn J. , Thompson M. , Mildvan D. , Pottage J. , Shepp D. , van der Horst C. , & Delehanty J. Selection of FTC dose based on viral kinetics and pharmacokinetics in an accelerated clinical trial design. 12th World AIDS Conference, Geneva, Switzerland, July 1998; Abstract 12208.

Delehanty J. , Wakeford C. , Hulett L. , Quinn J. , McCreedy B. , Almond M. , Miralles D. , & Rousseau F. A Phase I/II randomized, controlled study of FTC versus 3TC in HIV-infected patients. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., January 1999; Abstract 16.

Molina J-M , Rancinan C. , Ferchal F. , Raffi F. , Rozenbaum W. , Sereni D. , Morlat P. , Perusat S. , & Chene G. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment naive HIV-infected adults: 48-week follow-up of the ANRS 091 trial. Infectious Diseases Society of America annual conference, New Orleans, La., September 2000; Abstract 648.

Molina J-M , Ferchal F. , Rancinan C. , Raffi F. , Rozenbaum W. , Sereni D. , Morlat P. , Journot V. , Decazes J-M , & Chêne J. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus–infected patients. Journal of Infectious Diseases 2000; 182: 599–602.